SCHEMBL1068404

SCHEMBL1068404

Fc1[c]cccc1C1CC1

nearest known ligand 0.38

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
HTR2C P28335 9/20 0.38
HTR1A P08908 8/20 0.34
SLC6A2 P23975 8/20 0.34
SLC6A4 P31645 8/20 0.34
SLC6A3 Q01959 7/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL432692 0.90 PTGS2 (0.37) HTR2CHTR1ASLC6A2SLC6A4SLC6A3
SCHEMBL2783168 0.80 DRD2 (0.40) SLC6A4
SCHEMBL2784809 0.78 DRD2 (0.55) SLC6A4
SCHEMBL2782663 0.77 SIGMAR1 (0.42) HTR1ASLC6A4
SCHEMBL455259 0.76 HTR2C (0.39) HTR2C
SCHEMBL16958502 0.76 HTR2C (0.31) HTR2C
SCHEMBL9586481 0.76 HTR2C (0.31) HTR2C
SCHEMBL2805088 0.74 DRD2 (0.45) HTR1ASLC6A4
SCHEMBL456171 0.74 TP53 (0.33) HTR2C
SCHEMBL16960341 0.74 HTR2C (0.31) HTR2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118265702-A Microbiocidal isonicotinamide derivatives 先正达农作物保护股份公司 2024-06-28 CN claimed
US-20240208902-A1 CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2024-06-27 US claimed
WO-2024132895-A1 MICROBIOCIDAL DIHYDROOXADIAZINYL PYRIDAZINONE COMPOUNDS SYNGENTA CROP PROTECTION AG (CH) 2024-06-27 WO claimed
WO-2024132901-A1 MICROBIOCIDAL PYRIDAZINE DIHYDROOXADIAZINE DERIVATIVES SYNGENTA CROP PROTECTION AG (CH) 2024-06-27 WO claimed
WO-2024089191-A1 MICROBIOCIDAL HETEROBICYCLIC DIHYDROOXADIAZINE DERIVATIVES SYNGENTA CROP PROTECTION AG (CH) 2024-05-02 WO claimed
WO-2024068976-A1 AZOLE DERIVATIVES AS SHP2 INHIBITORS IRBM S.P.A. (IT) 2024-04-04 WO claimed
EP-4345101-A1 AZOLE DERIVATIVES AS SHP2 INHIBITORS IRBM S.P.A. (IT) 2024-04-03 EP claimed
US-20240016152-A1 ACTIVE COMPOUND COMBINATIONS BAYER AKTIENGESELLSCHAFT (DE) 2024-01-18 US claimed
US-11802111-B2 Cyclobutyl amide monoacylglycerol lipase modulators JANSSEN PHARMACEUTICA NV (BE) 2023-10-31 US claimed
EP-4217062-A1 CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS JANSSEN Pharmaceutica NV (BE) 2023-08-02 EP claimed
WO-2023089049-A2 MICROBIOCIDAL ISONICOTINIC AMIDE DERIVATIVES SYNGENTA CROP PROTECTION AG (CH) 2023-05-25 WO claimed
EP-4167740-A1 ACTIVE COMPOUND COMBINATIONS Bayer Aktiengesellschaft (DE) 2023-04-26 EP claimed
CN-115955916-A Active compound combinations 拜耳公司 2023-04-11 CN claimed
WO-2021255070-A1 ACTIVE COMPOUND COMBINATIONS BAYER AKTIENGESELLSCHAFT (DE) 2021-12-23 WO claimed
US-9890167-B2 Pyrazine compounds for the treatment of infectious diseases HOFFMANN-LA ROCHE INC. (US) 2018-02-13 US claimed
EP-3245206-A1 PYRAZINE COMPOUNDS FOR THE TREATMENT OF INFECTIOUS DISEASES F. Hoffmann-La Roche AG (CH) 2017-11-22 EP claimed
US-20160237090-A1 NOVEL PYRAZINE COMPOUNDS FOR THE TREATMENT OF INFECTIOUS DISEASES HOFFMANN-LA ROCHE INC. (US) 2016-08-18 US claimed
WO-2016113273-A1 PYRAZINE COMPOUNDS FOR THE TREATMENT OF INFECTIOUS DISEASES F. HOFFMANN-LA ROCHE AG (CH) 2016-07-21 WO claimed
US-7741327-B2 Pyrrolidinone glucokinase activators HOFFMANN-LA ROCHE INC. (US) 2010-06-22 US claimed
US-20090264445-A1 PYRROLIDINONE GLUCOKINASE ACTIVATORS BERTHEL STEVEN JOSEPH 2009-10-22 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240016152-A1 ACTIVE COMPOUND COMBINATIONS CYP51A1, ERG28, BROX HTR2C 4661/4885HTR1A 4719/4885SLC6A2 4686/4885
US-20090264445-A1 PYRROLIDINONE GLUCOKINASE ACTIVATORS GCKR, GCK, PDK2 HTR2C 3892/4885HTR1A 4454/4885SLC6A2 3967/4885
US-20160237090-A1 NOVEL PYRAZINE COMPOUNDS FOR THE TREATMENT OF INFECTIOUS DISEASES HAVCR2, NR1H4, ZC3HAV1 HTR2C 2259/4885HTR1A 2632/4885SLC6A2 4371/4885
US-20240208902-A1 CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS MGLL, LPL, PNLIP HTR2C 457/4885HTR1A 318/4885SLC6A2 1255/4885
US-11802111-B2 Cyclobutyl amide monoacylglycerol lipase modulators MGLL, LPL, PNLIP HTR2C 438/4885HTR1A 315/4885SLC6A2 1259/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.